Caso clínico: tromboembolismo pulmonar secundário em um paciente com COVID-19
DOI:
https://doi.org/10.11606/issn.2176-7262.v53i3p313-320Palavras-chave:
COVID-19, SARS-CoV-2, Tromboembolismo PulmonarResumo
A COVID-19 é a doença infecciosa cujo agente etiológico é um betacoronavirus, o SARS-CoV-2. Sua emergência se deu em uma província chinesa em dezembro de 2019, tornando-se uma pandemia que desafia a saúde pública global. Habitualmente, apresenta-se como uma síndrome gripal, com possibilidade de evolução para síndrome respiratória aguda grave. Além disso, pode provocar alterações na coagulação e resposta inflamatória do indivíduo, levando a complicações tromboembólicas. Este artigo relata o caso de um paciente de 58 anos, diagnosticado com COVID-19, que seguia em isolamento domiciliar e, evoluiu com dispneia e hemoptise no quarto dia de doença. O diagnóstico do tromboembolismo pulmonar (TEP) foi confirmado através de tomografia contrastada de tórax. O paciente foi internado para tratamento clínico, necessitando de acompanhamento em Unidade de Terapia Intensiva (UTI) entre o terceiro e quinto dia de internação. Após alta da UTI, o paciente evoluiu sem demais intercorrências, recebendo alta no décimo dia de internação hospitalar.
Downloads
Referências
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020 Mar 17;26(4):450–2.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;1–13.
Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;0–2.
Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol [Internet]. 2020;104362. Available from: https://doi.org/10.1016/j.jcv.2020.104362
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med [Internet]. 2020 Apr 8 [cited 2020 Apr 16];e38. Available from: http://www.nejm.org/doi/10.1056/NEJMc2007575
Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect [Internet]. 2020;(xxxx):17–9. Available from: https://doi.org/10.1016/j.jmii.2020.03.005
Xie Y, Wang X, Yang P, Zhang S. COVID-19 Complicated by Acute Pulmonary Embolism. Radiol Cardiothorac Imaging. 2020;2(2):e200067.
Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 novel coronavirus (2019-NCoV). Radiology. 2020 Feb 4;295(1):202–7.
Konstantinides S V., Meyer G, Bueno H, Galié N, Gibbs JSR, Ageno W, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS) [Internet]. Vol. 41, European Heart Journal. Poland; 2020 [cited 2020 Apr 18]. p. 543–603. Available from: https://academic.oup.com/eurheartj/article-abstract/41/4/543/5556136
Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;2020.
Casey K, Iteen A, Nicolini R, Auten J. COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med [Internet]. 2020 Apr [cited 2020 Apr 18]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735675720302394
Chate RC, Kaiser E, Nunes U, Bastos R, Passos D, Borges G, et al. Apresentação tomográfica da infecção pulmonar na COVID-19 : experiência brasileira inicial. J Bras Pneumol. 2020;46(2):2–5.
Ministério da Saúde. Diretrizes para o diagnóstico e tratamento da COVID-19 [Internet]. Secretaria de Ciência, Tecnologia, Inovação e Saúde. Insumos Estratégicos em Saúde. 2020 [cited 2020 Apr 19]. Available from: https://portalarquivos.saude.gov.br/images/pdf/2020/April/07/ddt-covid-19.pdf
Yumeng Y, Cao J, Qingqing W, Liu K, Zheo L, Kaihuan Y, et. al D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. 2020 Apr 4;
Klok FA, Kruip MJHA, Meer NJM Van Der, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res [Internet]. 2020;(xxxx):1–3. Available from: https://doi.org/10.1016/j.thromres.2020.04.013
Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological Study of the 2019 Novel Coronavirus Disease (COVID-19) through Post-Mortem Core Biopsies. Preprints [Internet]. 2020;10–2. Available from: https://www.preprints.org/manuscript/202003.0311/v1
Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis [Internet]. 2020;3–6. Available from: https://doi.org/10.1007/s11239-020-02105-8
Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;2019:4–9.
Ministério da Saúde Secretaria de Vigilância em Saúde Departamento de Vigilância das Doenças Transmissíveis B. Protocolo de tratamento de Influenza: 2017 [recurso eletrônico] [Internet]. [cited 2020 Apr 19]. Available from: http://bvsms.saude.gov.br/publicacoes/protocolo_tratamento_
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med [Internet]. 2020 Jul 23 [cited 2020 Aug 9]; Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2019014
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med [Internet]. 2020 Jul 17 [cited 2020 Aug 9];NEJMoa2021436. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2021436
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury [Internet]. Vol. 395, The Lancet. Lancet Publishing Group; 2020 [cited 2020 Aug 15]. p. 473–5. Available from: https://doi.org/10.1016/S0140-6736
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc [Internet]. 2020 Mar 17 [cited 2020 Aug 15];323(11):1061–9. Available from: https://jamanetwork.com/
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2020 André Luiz Cicilini, Alana Ferreira de Oliveira, Cássio Murilo Trovo Hidalgo Filho, Renata Freitas Nogueira Salles, Michele Higa Fróes, Jamilton de Medeiros Eduardo
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
